Ping Ma

Ping Ma

Auto-generated profile, based on publicly available information

Ping Ma

Department of Medical Oncology, Guangzhou No. 12 People’s Hospital, Guangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZDZefeng Du
Zefeng Du
ZLZhicheng Lai
Zhicheng Lai
YHYexing Huang
Yexing Huang
HCHailong Chen
Hailong Chen
PMPing Ma
Ping Ma
MHMinke He
Minke He
Purpose: Immune checkpoint inhibitor (ICI)–related trials in hepatocellular carcinoma (HCC) have strict restrictions on hepatitis B (HBV) DNA load because of HBV reactivation. This study aimed to compare the HBV reactivation between patients with HCC with low or high HBV DNA loads receiving ICIs and antiviral therapy. Patients and Methods: This prospective observational study (NCT04680598) recruited hepatitis B surface antigen–positive patients with HCC who received concurrent antiviral therapy with initial ICI treatment. Participants were divided into HBV DNA–low (≤500 IU/mL) and HBV DNA–high (>500 IU/mL) groups. The primary endpoint was the HBV reactivation rate. Results: Between December 25, 2020, and February 23, 2024, 356 and 659 participants were enrolled in the HBV DNA–low and HBV DNA–high groups. The HBV DNA–high group included significantly higher proportions of patients with hepatitis Be antigen positivity (24.1% vs. 7.0%, P < 0.001), albumin–bilirubin grade 2 to 3 (49.9% vs. 33.7%, P < 0.001), and Barcelona Clinic Liver Cancer stage C (83.3% vs. 72.5%, P < 0.001). The HBV reactivation rate (4.5% vs. 6.1%, relative risk, 1.24; 95% confidence interval, 0.81–1.89; P = 0.29), frequencies of HBV reactivation–associated hepatitis (1.7% vs. 2.3%, P = 0.53), and interruptions in ICI treatment (25.8% vs. 30.5%, P = 0.12) were comparable in the HBV DNA–low group and HBV DNA–high group. Conclusions: There was no significant difference in the risk of HBV reactivation between patients with HCC with HBV DNA ≤500 IU/mL and those with HBV DNA >500 IU/mL when treated with ICIs and concurrent antiviral prophylaxis.


17 February 2026
Verified
Other
Open access
ZDZefeng Du
Zefeng Du
ZLZhicheng Lai
Zhicheng Lai
YHYexing Huang
Yexing Huang
HCHailong Chen
Hailong Chen
PMPing Ma
Ping Ma
MHMinke He
Minke He
Purpose:Immune checkpoint inhibitor (ICI)–related trials in hepatocellular carcinoma (HCC) have strict restrictions on hepatitis B (HBV) DNA load because of HBV reactivation. This study aimed to compare the HBV reactivation between patients with HCC with low or high HBV DNA loads receiving ICIs and antiviral therapy.Patients and Methods:This prospective observational study (NCT04680598) recruited hepatitis B surface antigen–positive patients with HCC who received concurrent antiviral therapy with initial ICI treatment. Participants were divided into HBV DNA–low (≤500 IU/mL) and HBV DNA–high (>500 IU/mL) groups. The primary endpoint was the HBV reactivation rate.Results:Between December 25, 2020, and February 23, 2024, 356 and 659 participants were enrolled in the HBV DNA–low and HBV DNA–high groups. The HBV DNA–high group included significantly higher proportions of patients with hepatitis Be antigen positivity (24.1% vs. 7.0%, P < 0.001), albumin–bilirubin grade 2 to 3 (49.9% vs. 33.7%, P < 0.001), and Barcelona Clinic Liver Cancer stage C (83.3% vs. 72.5%, P < 0.001). The HBV reactivation rate (4.5% vs. 6.1%, relative risk, 1.24; 95% confidence interval, 0.81–1.89; P = 0.29), frequencies of HBV reactivation–associated hepatitis (1.7% vs. 2.3%, P = 0.53), and interruptions in ICI treatment (25.8% vs. 30.5%, P = 0.12) were comparable in the HBV DNA–low group and HBV DNA–high group.Conclusions:There was no significant difference in the risk of HBV reactivation between patients with HCC with HBV DNA ≤500 IU/mL and those with HBV DNA >500 IU/mL when treated with ICIs and concurrent antiviral prophylaxis.

17 February 2026
Verified
Other
Open access
ZDZefeng Du
Zefeng Du
ZLZhicheng Lai
Zhicheng Lai
YHYexing Huang
Yexing Huang
HCHailong Chen
Hailong Chen
PMPing Ma
Ping Ma
MHMinke He
Minke He
Supplementary Figure 1. HBV DNA dynamics in patients with HBV reactivation from the prospective cohort and the NCT02973685 cohort.

17 February 2026
Verified
Other
Open access
ZDZefeng Du
Zefeng Du
ZLZhicheng Lai
Zhicheng Lai
YHYexing Huang
Yexing Huang
HCHailong Chen
Hailong Chen
PMPing Ma
Ping Ma
MHMinke He
Minke He
Supplementary Table 7. Univariate and multivariate analysis of HBV DNA reactivation among two cohorts.

17 February 2026
Verified
Other
Open access
ZDZefeng Du
Zefeng Du
ZLZhicheng Lai
Zhicheng Lai
YHYexing Huang
Yexing Huang
HCHailong Chen
Hailong Chen
PMPing Ma
Ping Ma
MHMinke He
Minke He
Supplementary Table 6. Tumor response in patients received ICIs monotherapy or combination therapy